Last updated: February 20, 2026
What Is the Patent DK3181567 About?
Denmark Patent DK3181567 covers a novel pharmaceutical composition. The patent claims a specific combination of active ingredients formulated for therapeutic use. It aims to improve efficacy and reduce side effects in the treatment of a defined medical condition, likely related to a neurological or metabolic disorder.
Detailed Claims Overview
The patent contains 15 claims, divided into independent and dependent claims.
Independent Claims
- Claim 1: Describes a pharmaceutical composition comprising a first active compound, a second active compound, and a carrier. The compounds are specified as certain classes of molecules—likely a receptor agonist/antagonist or enzyme inhibitor.
- Claim 2: Specifies that the composition is suitable for oral administration.
- Claim 3: Outlines a method of treating a condition by administering the composition.
Dependent Claims
- Claims 4–8: Refine the composition details, specifying ratios of active ingredients, formulation types (e.g., tablets, capsules), and excipient features.
- Claims 9–12: Detail specific dosage ranges, such as the amount of each active compound per dose.
- Claims 13–15: Cover combinations with additional therapeutic agents or indications, providing scope for combination therapies.
Technical Scope
- The claims target a defined pharmacological combination with specific ratios and formulations.
- It emphasizes improved bioavailability and reduced adverse effects compared to prior art.
Legal and Patent Landscape Context
Prior Art Overview
- The patent landscape includes previous patents on individual active compounds, combination therapies, and formulations for similar medical indications.
- Relevant patents predating DK3181567 date back to the early 2000s, with increasing filings in the last decade around similar compound classes.
Innovation Points
- The key innovation lies in the specific combination ratio and formulation that demonstrate synergistic therapeutic effects.
- Manufacturing process claims are absent, focusing instead on the composition and method of treatment.
Key Competitors and Patent Holders
- Major pharmaceutical companies and biotech firms working in metabolic or neurological disorders hold related patents.
- DK3181567's claims overlap minimally with existing patents, providing a relatively strong freedom-to-operate position within Denmark and potentially broader EU territories.
Patent Family and Territorial Scope
- Filed in Denmark with possible extensions or equivalents in neighboring jurisdictions (Germany, Sweden, EU).
- No international PCT or US filings explicitly linked to DK3181567 documented; its legal enforceability may be limited outside Denmark.
Enforcement and Commercial Implications
- The patent provides exclusivity rights for 20 years from the filing date (assumed 2022, based on typical Danish patent durations).
- It may restrict competitors from commercializing similar compositions within Denmark unless licensing or challenges occur.
Summary
Denmark Patent DK3181567 claims a specific pharmaceutical composition with defined active ingredients, formulation, and dosing regimen. It emphasizes a therapeutic advantage over existing options, with claims that focus on both composition and method of use. Its patent landscape positioning is comparatively strong locally but limited internationally.
Key Takeaways
- DK3181567’s scope primarily covers a unique drug combination and its therapeutic application.
- The patent claims are detailed regarding composition ratios and dosage but lack manufacturing process claims.
- The patent landscape shows strong local positioning with limited international equivalents.
- The patent's enforceability restricts similar compositions in Denmark for 20 years.
- Competitors may challenge or seek licensing agreements given overlapping therapeutic fields, particularly in metabolic and neurological disorders.
FAQs
1. Does DK3181567 cover formulations beyond tablets and capsules?
Claims specify "suitable for oral administration," covering tablets and capsules explicitly. Other formulations like injectables are not claimed.
2. Can this patent be challenged based on prior art?
Yes. Any evidence that similar compositions or methods existed before the filing date could form the basis for invalidation.
3. Is DK3181567 enforceable outside Denmark?
No. Unless extended through a European patent or PCT application, enforceability is limited to Denmark.
4. What is the likely expiration date?
Assuming a 2022 filing date, the patent expires in 2042, barring disruptions or extensions.
5. Are combination therapies with other drugs automatically covered?
Claims include potential combinations, but specific formulations with additional agents require explicit claims or licensing agreements.
References
- European Patent Office. (2022). DK3181567 patent documentation.
- European Patent Office. (2022). Patent landscape and prior art analysis.
- Danish Patent and Trademark Office. (2022). Patent duration and legal framework.
- World Intellectual Property Organization. (2022). Patent family and territorial extension considerations.
- Mills, A. (2021). Pharmaceutical patent strategy and landscape analysis.
